Finance

Lists
Why is 2359 down 2,19%?
Dive Deeper
2359:HKG
WuXi AppTec Ord Shs H
196,20 HK$
-2,19%
(-4,40) 1D
16 қаз., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2359...
Open
203,80 HK$
High
209,00 HK$
Low
185,00 HK$
Mkt. cap
544,52 млрд
Avg. vol.
3,91 млн
Volume
10,16 млн
Dividend
1,22%
Quarterly dividend
0,60 HK$
Ex-dividend date
2026 ж. 04 қыр.
P/E ratio
23,98
52-wk high
219,20 HK$
52-wk low
96,70 HK$
EPS
8,18 HK$
No. of employees
36 мың
Open
203,80 HK$
High
209,00 HK$
Low
185,00 HK$
Mkt. cap
544,52 млрд
Avg. vol.
3,91 млн
Volume
10,16 млн
Dividend
1,22%
Quarterly dividend
0,60 HK$
Ex-dividend date
2026 ж. 04 қыр.
P/E ratio
23,98
52-wk high
219,20 HK$
52-wk low
96,70 HK$
EPS
8,18 HK$
No. of employees
36 мың
News stories
From web sources and news partners
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35,6 мың
Founded2000 ж. 01 жел.
Headquarters-
Sector-
Last report
2026 ж. 03 там.
Fiscal period
Q2 2026
2,20 CN¥ / 1,34 CN¥
+64,18%beat
Revenue / Est. (CNY)
16,46 млрд / 12,86 млрд
+28,03%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
12,04 млрд
10,97 млрд
12,44 млрд
16,46 млрд
Cost of goods sold
6,07 млрд
4,91 млрд
6,17 млрд
-
Cost of revenue
6,07 млрд
4,91 млрд
6,17 млрд
-
Research and development expenses
311,73 млн
236,94 млн
266,96 млн
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
854,49 млн
853,67 млн
891,80 млн
-
Operating expense
1,38 млрд
1,26 млрд
1,22 млрд
-
Total operating expenses
7,45 млрд
6,17 млрд
7,39 млрд
-
Operating income
4,59 млрд
4,80 млрд
5,04 млрд
-
Other non operating income
-470,36 млн
281,37 млн
-266,37 млн
-
EBT including unusual items
5,13 млрд
6,75 млрд
5,61 млрд
-
EBT excluding unusual items
5,11 млрд
6,95 млрд
5,19 млрд
-
Income tax expense
1,55 млрд
1,09 млрд
936,77 млн
-
Effective tax rate
30,19%
16,12%
16,71%
-
Other operating expenses
57,96 млн
25,84 млн
726,05 м.
-
Net income
3,51 млрд
7,08 млрд
4,65 млрд
-
Net profit margin
29,18%
64,49%
37,40%
-
Earnings per share
1,24
1,42
1,57
2,20
Interest and investment income
1,21 млрд
1,87 млрд
439,82 млн
-
Interest expense
-226,71 млн
-
-30,95 млн
-
Net interest expenses
981,72 млн
1,87 млрд
408,87 млн
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5,21 млрд
5,61 млрд
5,85 млрд
-
Gain or loss from assets sale
-158,03 млн
218,40 млн
-
-
AI content may include mistakes. Learn more
Google қолданбалары